broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
null | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K71847383-001-12-5 | ACH-000879 | MFE296_ENDOMETRIUM | HTS002 | 1 | 2.122352 | -0.022826 | -0.026964 | 1.677789 | 8,415,092.899292 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000879 |
BRD-K71847383-001-12-5 | ACH-000320 | PSN1_PANCREAS | HTS002 | 1 | 1.325174 | -0.237504 | -0.147274 | 1.2403 | 9.643742 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000320 |
BRD-K71847383-001-12-5 | ACH-001145 | OC316_OVARY | HTS002 | 1 | 2.08935 | -0.302937 | 0.193893 | 1.472333 | 0.027767 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001145 |
BRD-K71847383-001-12-5 | ACH-000873 | KYSE270_OESOPHAGUS | HTS002 | 1 | 1.31182 | -0.209393 | -0.00546 | 1.20716 | 2.654701 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000873 |
BRD-K71847383-001-12-5 | ACH-000855 | KYSE150_OESOPHAGUS | HTS002 | 1 | 1.369799 | -0.27753 | 0.132818 | 1.229332 | 0.588904 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000855 |
BRD-K71847383-001-12-5 | ACH-000913 | ESS1_ENDOMETRIUM | HTS002 | 1 | 2.433246 | -1.435943 | 0.168739 | 1.130378 | 0.001172 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000913 |
BRD-K71847383-001-12-5 | ACH-000558 | A172_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.78623 | 0.074955 | -0.029545 | 1.43674 | 0.003867 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000558 |
BRD-K71847383-001-12-5 | ACH-000593 | BC3C_URINARY_TRACT | HTS002 | 1 | 1.949354 | -0.192403 | 0.174755 | 1.328064 | 0.002247 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000593 |
BRD-K71847383-001-12-5 | ACH-000488 | TE11_OESOPHAGUS | HTS002 | 1 | 1.43101 | -0.220304 | 0.098313 | 1.200396 | 0.038911 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000488 |
BRD-K71847383-001-12-5 | ACH-000832 | CAL27_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.80839 | -0.098703 | -0.098915 | 1.335735 | 0.002288 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000832 |
BRD-K71847383-001-12-5 | ACH-000781 | NCIH2023_LUNG | HTS002 | 1 | 1.96334 | -0.157777 | 0.128698 | 1.467798 | 0.053276 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000781 |
BRD-K71847383-001-12-5 | ACH-000137 | 8MGBA_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 4.750272 | 0.303556 | -0.111814 | 1.113997 | 20,095.432688 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000137 |
BRD-K71847383-001-12-5 | ACH-000632 | HS944T_SKIN | HTS002 | 1 | 2.144612 | -0.175569 | 0.328183 | 1.503386 | 0.018135 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000632 |
BRD-K71847383-001-12-5 | ACH-000319 | MPP89_PLEURA | HTS002 | 1 | 1.542258 | -0.055698 | -0.121322 | 1.379969 | 366,459.712136 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000319 |
BRD-K71847383-001-12-5 | ACH-000630 | YD8_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.894104 | -0.33901 | 0.145696 | 1.387071 | 0.029701 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000630 |
BRD-K71847383-001-12-5 | ACH-000266 | SNU213_PANCREAS | HTS002 | 1 | 2.057154 | -0.020719 | 0.005638 | 1.535763 | 0.290571 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000266 |
BRD-K71847383-001-12-5 | ACH-000047 | GCIY_STOMACH | HTS002 | 1 | 0.982869 | 1.297144 | -0.097755 | 0.99094 | 0.058964 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000047 |
BRD-K71847383-001-12-5 | ACH-000273 | SF539_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 2.102617 | -0.016699 | -0.009315 | 1.555969 | 0.215165 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000273 |
BRD-K71847383-001-12-5 | ACH-000682 | SNU1066_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.599211 | -0.323113 | -0.10721 | 0.882446 | 0.003114 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000682 |
BRD-K71847383-001-12-5 | ACH-000359 | MG63_BONE | HTS002 | 1 | 0.733572 | -0.693434 | 0.122409 | 0.905373 | 0.017 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000359 |
BRD-K71847383-001-12-5 | ACH-000846 | FADU_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 0.689928 | 0.251677 | 0.176607 | 0.84035 | 0.059922 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000846 |
BRD-K71847383-001-12-5 | ACH-000804 | NB1_AUTONOMIC_GANGLIA | HTS002 | 1 | 1.011043 | 0.151074 | -0.005991 | 1.005126 | 0.210465 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000804 |
BRD-K71847383-001-12-5 | ACH-000609 | SF126_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 0.802225 | -0.085226 | -0.080794 | 0.874109 | 61.342199 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000609 |
BRD-K71847383-001-12-5 | ACH-000974 | SNGM_ENDOMETRIUM | HTS002 | 1 | 3.03257 | 1.655876 | -0.193973 | 1.000528 | 273.23 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000974 |
BRD-K71847383-001-12-5 | ACH-000987 | MEWO_SKIN | HTS002 | 1 | 1.007962 | -0.263855 | -0.12153 | 1.005038 | 0.802389 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000987 |
BRD-K71847383-001-12-5 | ACH-000787 | LXF289_LUNG | HTS002 | 1 | 1.510421 | -0.274899 | 0.056012 | 1.096079 | 0.000201 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000787 |
BRD-K71847383-001-12-5 | ACH-000561 | TT_OESOPHAGUS | HTS002 | 1 | 1.247121 | -0.019809 | 0.005774 | 1.121053 | 0.010051 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000561 |
BRD-K71847383-001-12-5 | ACH-000212 | CAL120_BREAST | HTS002 | 1 | 1.172737 | 5.356881 | -0.08334 | 1.111354 | 0.019195 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000212 |
BRD-K71847383-001-12-5 | ACH-000753 | JMSU1_URINARY_TRACT | HTS002 | 1 | 1.97744 | 0.356437 | -0.081285 | 1.369569 | 0.436467 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000753 |
BRD-K71847383-001-12-5 | ACH-000305 | ECGI10_OESOPHAGUS | HTS002 | 1 | 1.353783 | -0.178115 | -0.026861 | 1.184637 | 0.131692 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000305 |
BRD-K71847383-001-12-5 | ACH-000138 | CFPAC1_PANCREAS | HTS002 | 1 | 1.179622 | 0.005991 | -0.034276 | 1.088015 | 62.186931 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000138 |
BRD-K71847383-001-12-5 | ACH-000250 | KMRC20_KIDNEY | HTS002 | 1 | 1.137318 | 0.402542 | 0.026051 | 1.033079 | 2.893364 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000250 |
BRD-K71847383-001-12-5 | ACH-000856 | CAL51_BREAST | HTS002 | 1 | 1.570118 | -0.391067 | 0.161732 | 1.320316 | 0.176486 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000856 |
BRD-K71847383-001-12-5 | ACH-000046 | ACHN_KIDNEY | HTS002 | 1 | 1.973399 | 0.203092 | -0.177348 | 1.307926 | 4.63 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000046 |
BRD-K71847383-001-12-5 | ACH-000878 | HCC15_LUNG | HTS002 | 1 | 1.276811 | 0.423643 | -0.19365 | 1.161206 | 0.027591 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000878 |
BRD-K71847383-001-12-5 | ACH-000766 | NCIH1648_LUNG | HTS002 | 1 | 1.356497 | 0.251445 | -0.144285 | 1.179586 | 0.073066 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000766 |
BRD-K71847383-001-12-5 | ACH-000666 | NCIH1355_LUNG | HTS002 | 1 | 2.688037 | 0.002436 | -0.000447 | 1.83814 | 23.774893 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000666 |
BRD-K71847383-001-12-5 | ACH-000014 | HS294T_SKIN | HTS002 | 1 | 1.736533 | -3.519942 | 0.209834 | 1.352513 | 0.063481 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000014 |
BRD-K71847383-001-12-5 | ACH-000701 | RMUGS_OVARY | HTS002 | 1 | 2.306763 | -0.334336 | 0.066222 | 1.319396 | 0.001413 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000701 |
BRD-K71847383-001-12-5 | ACH-000884 | MDAMB435S_SKIN | HTS002 | 1 | 1.495186 | -1.412309 | -0.06372 | 1.184753 | 0.022707 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000884 |
BRD-K71847383-001-12-5 | ACH-000504 | SNB75_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.626684 | -9.720646 | 0.242547 | 1.399741 | 0.297728 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000504 |
BRD-K71847383-001-12-5 | ACH-000502 | TCCPAN2_PANCREAS | HTS002 | 1 | 1.556409 | -0.741207 | 0.185838 | 1.191476 | 0.015475 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000502 |
BRD-K71847383-001-12-5 | ACH-000886 | NCIH2009_LUNG | HTS002 | 1 | 1.933061 | -0.603979 | -0.017778 | 1.443687 | 0.059969 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000886 |
BRD-K71847383-001-12-5 | ACH-000035 | NCIH1650_LUNG | HTS002 | 1 | 1.648817 | -2.658655 | 0.307478 | 1.386549 | 0.197893 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000035 |
BRD-K71847383-001-12-5 | ACH-000661 | WM1799_SKIN | HTS002 | 1 | 1.137175 | -0.219573 | -0.130107 | 1.090688 | 2.151031 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000661 |
BRD-K71847383-001-12-5 | ACH-000391 | MHHES1_BONE | HTS002 | 1 | 1.101463 | 0.146963 | -0.022932 | 1.064826 | 0.001372 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000391 |
BRD-K71847383-001-12-5 | ACH-000843 | HARA_LUNG | HTS002 | 1 | 1.792085 | -2.132069 | 0.632434 | 1.438149 | 0.130869 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000843 |
BRD-K71847383-001-12-5 | ACH-000711 | JIMT1_BREAST | HTS002 | 1 | 1.812952 | -0.080722 | -0.057074 | 1.420198 | 0.182304 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000711 |
BRD-K71847383-001-12-5 | ACH-000232 | U251MG_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.903037 | -0.228779 | 0.404941 | 1.342351 | 0.007312 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000232 |
BRD-K71847383-001-12-5 | ACH-000060 | PANC1005_PANCREAS | HTS002 | 1 | 2.792043 | -0.617184 | 0.248363 | 1.289292 | 0.001361 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000060 |
BRD-K71847383-001-12-5 | ACH-000736 | SNU601_STOMACH | HTS002 | 1 | 1.271749 | 0.088243 | -0.021303 | 1.159139 | 0.001462 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000736 |
BRD-K71847383-001-12-5 | ACH-000809 | KYSE410_OESOPHAGUS | HTS002 | 1 | 1.422825 | -0.371051 | -0.062547 | 1.225799 | 0.123933 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000809 |
BRD-K71847383-001-12-5 | ACH-000747 | NCIH1703_LUNG | HTS002 | 1 | 2.042603 | -0.059189 | -0.013878 | 1.39679 | 0.00002 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000747 |
BRD-K71847383-001-12-5 | ACH-000364 | U2OS_BONE | HTS002 | 1 | 1.65522 | -0.289141 | 0.046196 | 1.307502 | 0.04774 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000364 |
BRD-K71847383-001-12-5 | ACH-000679 | OE19_OESOPHAGUS | HTS002 | 1 | 1.813996 | -0.089484 | 0.048039 | 1.378985 | 0.016337 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000679 |
BRD-K71847383-001-12-5 | ACH-000985 | LS411N_LARGE_INTESTINE | HTS002 | 1 | 1.231335 | -0.001359 | -0.010766 | 1.116323 | 326.183562 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000985 |
BRD-K71847383-001-12-5 | ACH-000441 | SH4_SKIN | HTS002 | 1 | 1.372867 | 0.145105 | -0.105724 | 1.181955 | 0.110285 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000441 |
BRD-K71847383-001-12-5 | ACH-001113 | LC1SQSF_LUNG | HTS002 | 1 | 1.658567 | 0.116132 | -0.120648 | 1.312522 | 0.192249 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001113 |
BRD-K71847383-001-12-5 | ACH-000620 | JHH1_LIVER | HTS002 | 1 | 1.752969 | -0.254885 | 0.123659 | 1.285903 | 0.009009 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000620 |
BRD-K71847383-001-12-5 | ACH-000853 | NCIH661_LUNG | HTS002 | 1 | 1.689289 | -0.008143 | -0.006801 | 1.347048 | 0.433205 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000853 |
BRD-K71847383-001-12-5 | ACH-000102 | GMS10_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.405265 | -0.555669 | -0.07751 | 1.141014 | 0.013984 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000102 |
BRD-K71847383-001-12-5 | ACH-000648 | NCIH28_PLEURA | HTS002 | 1 | 1.501956 | -0.024347 | -0.00387 | 1.239972 | 0.002115 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000648 |
BRD-K71847383-001-12-5 | ACH-001239 | WM2664_SKIN | HTS002 | 1 | 1.559267 | 0.072719 | -0.011224 | 1.344977 | 0.000105 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001239 |
BRD-K71847383-001-12-5 | ACH-001321 | TT_THYROID | HTS002 | 1 | 1.534746 | 0.099931 | -0.047879 | 1.238696 | 0.702783 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001321 |
BRD-K71847383-001-12-5 | ACH-000279 | EWS502_BONE | HTS002 | 1 | 1.407583 | -0.059093 | -0.037438 | 1.331711 | 6,277,572,691.02502 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000279 |
BRD-K71847383-001-12-5 | ACH-000172 | TM87_SOFT_TISSUE | HTS002 | 1 | 1.235192 | -0.155161 | 0.036348 | 1.146125 | 2.197803 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000172 |
BRD-K71847383-001-12-5 | ACH-001128 | MON_SOFT_TISSUE | HTS002 | 1 | 2.229657 | 0.504519 | 0.234653 | 1.376345 | 0.791739 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001128 |
BRD-K71847383-001-12-5 | ACH-000437 | SW1088_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.551767 | 0.003152 | -0.057111 | 1.24203 | 749,079,266,429,778,000,000,000,000,000,000 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000437 |
BRD-K71847383-001-12-5 | ACH-000735 | PECAPJ49_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.66728 | 0.162644 | 0.030533 | 1.270144 | 0.941598 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000735 |
BRD-K71847383-001-12-5 | ACH-000643 | HDQP1_BREAST | HTS002 | 1 | 1.300983 | -0.002252 | -0.090685 | 1.229564 | 124,718,079,427,031,990,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000643 |
BRD-K71847383-001-12-5 | ACH-000207 | DETROIT562_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.573073 | -0.227289 | -0.085698 | 1.275321 | 0.053489 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000207 |
BRD-K71847383-001-12-5 | ACH-000456 | BCPAP_THYROID | HTS002 | 1 | 0.793404 | -0.072785 | 0.003761 | 0.886931 | 1.088019 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000456 |
BRD-K71847383-001-12-5 | ACH-000260 | SKNAS_AUTONOMIC_GANGLIA | HTS002 | 1 | 2.465575 | -0.246002 | 0.037561 | 1.330327 | 0.000309 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000260 |
BRD-K71847383-001-12-5 | ACH-000019 | MCF7_BREAST | HTS002 | 1 | 3.480451 | -1.351019 | 0.338182 | 1.117433 | 0.000546 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000019 |
BRD-K71847383-001-12-5 | ACH-000582 | COLO741_SKIN | HTS002 | 1 | 1.331186 | -0.036785 | -0.024406 | 1.161265 | 0.018786 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000582 |
BRD-K71847383-001-12-5 | ACH-000990 | HEC108_ENDOMETRIUM | HTS002 | 1 | 1.866183 | -0.323197 | 0.076346 | 1.466818 | 0.139222 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000990 |
BRD-K71847383-001-12-5 | ACH-000374 | HCC1143_BREAST | HTS002 | 1 | 1.337186 | -3.774497 | 0.205927 | 1.186465 | 0.130668 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000374 |
BRD-K71847383-001-12-5 | ACH-000759 | MDAMB175VII_BREAST | HTS002 | 1 | 31.004322 | 6.598629 | -0.050817 | 1 | 1,518,751.086006 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000759 |
BRD-K71847383-001-12-5 | ACH-000417 | PANC0813_PANCREAS | HTS002 | 1 | 1.328283 | -0.373733 | 0.163977 | 1.144888 | 0.035322 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000417 |
BRD-K71847383-001-12-5 | ACH-000308 | EFO21_OVARY | HTS002 | 1 | 2.114597 | -0.95661 | 0.00352 | 1.049944 | 0.000306 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000308 |
BRD-K71847383-001-12-5 | ACH-000991 | SNU81_LARGE_INTESTINE | HTS002 | 1 | 1.948835 | 0.106052 | -0.017725 | 1.428424 | 0.509029 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000991 |
BRD-K71847383-001-12-5 | ACH-000948 | 2313287_STOMACH | HTS002 | 1 | 1.778375 | -0.263089 | -0.135096 | 1.200618 | 0.000864 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000948 |
BRD-K71847383-001-12-5 | ACH-000481 | NCIH2170_LUNG | HTS002 | 1 | 2.119629 | -0.191805 | -0.016462 | 1.258869 | 0.0001 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000481 |
BRD-K71847383-001-12-5 | ACH-000771 | BICR56_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.817293 | -0.140247 | 0.00367 | 1.258888 | 0.000266 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000771 |
BRD-K71847383-001-12-5 | ACH-000159 | OSRC2_KIDNEY | HTS002 | 1 | 1.554384 | 0.348691 | -0.046052 | 1.115549 | 7.610348 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000159 |
BRD-K71847383-001-12-5 | ACH-000929 | NCIH2110_LUNG | HTS002 | 1 | 1.318948 | -0.00962 | -0.017966 | 1.184178 | 9,915,028,688,315.97 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000929 |
BRD-K71847383-001-12-5 | ACH-000118 | HUPT3_PANCREAS | HTS002 | 1 | 1.62972 | -0.031329 | -0.031623 | 1.322421 | 0.363028 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000118 |
BRD-K71847383-001-12-5 | ACH-000482 | RERFLCKJ_LUNG | HTS002 | 1 | 1.5697 | -0.062958 | -0.00052 | 1.2659 | 0.009258 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000482 |
BRD-K71847383-001-12-5 | ACH-000352 | HCC1428_BREAST | HTS002 | 1 | 1.347118 | -0.138262 | -0.051449 | 1.229072 | 11.219077 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000352 |
BRD-K71847383-001-12-5 | ACH-000235 | PANC0403_PANCREAS | HTS002 | 1 | 1.824181 | -0.243612 | -0.027092 | 1.393905 | 0.052171 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000235 |
BRD-K71847383-001-12-5 | ACH-000900 | NCIH23_LUNG | HTS002 | 1 | 1.497804 | -2.670336 | 0.277943 | 1.275023 | 0.129995 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000900 |
BRD-K71847383-001-12-5 | ACH-000479 | KNS81_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.567524 | -0.043777 | -0.08634 | 1.294179 | 0.421002 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000479 |
BRD-K71847383-001-12-5 | ACH-000401 | COLO800_SKIN | HTS002 | 1 | 1.237604 | -1.558154 | 0.038189 | 1.145062 | 0.228727 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000401 |
BRD-K71847383-001-12-5 | ACH-000276 | HCC38_BREAST | HTS002 | 1 | 1.528225 | -0.603912 | 0.047539 | 1.191256 | 0.01726 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000276 |
BRD-K71847383-001-12-5 | ACH-000724 | HT1376_URINARY_TRACT | HTS002 | 1 | 3.662735 | 0.270642 | -0.148154 | 1.146261 | 7,074.457907 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000724 |
BRD-K71847383-001-12-5 | ACH-000092 | NCIH2452_PLEURA | HTS002 | 1 | 2.047424 | -0.277374 | 0.0234 | 1.180893 | 0.000139 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000092 |
BRD-K71847383-001-12-5 | ACH-000890 | SW1271_LUNG | HTS002 | 1 | 1.731201 | -0.529288 | 0.156301 | 1.336417 | 0.049705 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000890 |
BRD-K71847383-001-12-5 | null | null | HTS002 | 1 | 1.573798 | -0.632507 | -0.001141 | 1.389931 | 0.552499 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | false | ACH-000539_FAILED_STR |
BRD-K71847383-001-12-5 | ACH-000800 | NCIH446_LUNG | HTS002 | 1 | 1.422689 | -3.980899 | 0.225771 | 1.072802 | 0.003246 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000800 |
BRD-K71847383-001-12-5 | ACH-000899 | WM88_SKIN | HTS002 | 1 | 1.969301 | -0.376862 | 0.446775 | 1.473547 | 0.066992 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000899 |
End of preview. Expand
in Dataset Viewer.
Citation
DepMap, Broad; Corsello, Steven; Kocak, Mustafa; Golub, Todd (2019). PRISM Repurposing 19Q4 Dataset. figshare. Dataset.
Current dataset: https://doi.org/10.6084/m9.figshare.9393293.v4
General guidance: https://doi.org/10.1101/730119
Dataset specific README: prism_repurposing_secondary
Dataset Fields
- broad_id: ID used to identify drug-batch combinations
- name: Name of the drug
- depmap_id: ID to identify a cell line
- ccle_name: ID to identify a cell line
- screen_id: ID to identify a screen
- upper_limit: Limit of the curve as dose approaches infinity
- lower_limit: Limit of the curve as dose approaches zero
- slope: Slope of the dose-response curve
- r2: Goodness of fit measure between dose-response curve and replicate viability data
- auc: Area under the dose-response curve
- ec50: Dose at the inflection point of the dose-response curve
- ic50: Dose that corresponds to a viability of 50 on the dose-response curve
- moa: Broad Repurposing Hub mechanism of action annotation
- target: Broad Repurposing Hub gene target annotation
- disease_area: Broad Repurposing Hub disease area annotation
- indication: Broad Repurposing Hub indication annotation
- smiles: Simplified Molecular Input Line Entry System (SMILES) molecular identifier
- phase: Broad Repurposing Hub latest clinical phase annotation
- passed_str_profiling: Indicator for problems identified by STR profiling
- Downloads last month
- 44